FDA Releases Draft CCS Guidance for Human Drugs and Biologics: Major Changes for Pharmaceutical CCIT (Container Closure Integrity Testing)

In August 2026, the FDA released two draft industry guidance documents on Container Closure Systems (CCS) for pharmaceuticals and biological products. The documents provide recommendations for the development and evaluation of container closure systems for human drugs, biological products and biosimilars. Both publications remain Draft Guidance at this stage; they are issued for public comment only and do not constitute enforceable mandatory requirements.

The core purpose of this guidance update is to further clarify the FDA’s overall expectations for the quality evaluation of pharmaceutical packaging systems. The FDA’s focus is no longer limited to whether individual packaging materials meet specifications. Instead, manufacturers are expected to conduct a comprehensive assessment of the safety, protective performance, functionality and lifecycle reliability of the complete container closure system.

Simply put, the core message delivered by this FDA update is: A pharmaceutical package is not merely a “container”. It constitutes a critical element that affects drug quality. Manufacturers must demonstrate that the packaging system can continuously protect the drug throughout its entire product lifecycle.

Key Content of the New FDA CCS Draft Guidance

The most significant change in the revised drafts is the FDA’s reinforced risk‑based management philosophy. Historically, pharmaceutical packaging evaluations largely followed standardized requirements, where different products were assessed against similar criteria for individual packaging components. The FDA now proposes that packaging risks vary from product to product due to differences in administration route, product characteristics, packaging configuration and storage conditions. A one‑size‑fits‑all evaluation approach is therefore inappropriate.

The FDA recommends that manufacturers perform a holistic risk assessment of the container closure system tailored to product‑specific attributes. Evaluation factors include packaging material safety, protective capability, functional performance, manufacturing‑related impacts, as well as storage and transportation conditions. In other words, a given packaging format is not universally suitable for all medicinal products. Companies must determine whether their selected packaging system adequately preserves drug quality on a product‑specific basis.

In addition, the new guidance broadens the scope of CCS evaluation. Beyond conventional pharmaceutical packaging systems, it covers device components within combination products and container closure systems for the drug portion of combination products. This means future packaging assessments will extend beyond traditional vials and stoppers to cover more complex drug‑delivery and packaging formats.

Critical Regulatory Signals from the New Guidance

Signal 1: Pharmaceutical packaging evaluation shifts from “compliance with specifications” to risk‑based scientific assessment

The most important regulatory shift reflected in this update is the change in oversight philosophy. In the past, companies often prioritized verifying whether packaging components complied with defined standards and supplier qualifications. The FDA now expects manufacturers to further prove that the fully assembled system maintains consistent drug protection over time. Future packaging evaluations will centre on product‑specific risks rather than a simplistic “pass/fail” judgement for a given packaging type. For example, a glass vial will carry vastly different sealing requirements and evaluation priorities for conventional formulations versus high‑risk sterile products. Manufacturers shall develop product‑specific CCS evaluation protocols accordingly.

Signal 2: E&L risk management gains greater prominence in packaging assessment

The guidance re‑emphasizes the importance of Extractables and Leachables (E&L). Certain chemical substances originating from packaging materials may migrate into the drug product and compromise patient safety. Manufacturers must therefore evaluate not only package seal integrity but also potential interactions between packaging materials and the drug formulation.

The FDA advises companies to scientifically assess chemicals released from packaging materials with toxicological risk considerations, incorporating concepts such as the Safety Concern Threshold (SCT), Analytical Evaluation Threshold (AET) and Qualification Threshold (QT). This evolution means packaging evaluation will no longer focus solely on physical performance; material safety and drug‑packaging compatibility will become essential evaluation pillars.

Signal 3: CCIT plays an increasingly vital role in sterile pharmaceutical packaging evaluation

For sterile medicinal products, Container Closure Integrity (CCI) is essential to maintaining product sterility. The updated guidance stresses that manufacturers must employ scientifically sound, reliable methods to demonstrate packaging integrity across the entire product lifecycle. For sterile injectables, ophthalmic preparations and similar products, package leakage can introduce microbial contamination and endanger product safety. Suitable integrity test methods shall be adopted, and Container Closure Integrity Testing (CCIT) shall be integrated into packaging validation and stability programmes.

The FDA also references advanced deterministic integrity test technologies including vacuum decay and high‑voltage leak detection, demonstrating the regulator’s preference for quantitative, robust and verifiable test methodologies.

Signal 4: Packaging evaluation expands to complex and novel packaging systems

The guidance addresses not only traditional pharmaceutical packaging but also an expanding range of complex products, including biosimilars, pre‑filled syringes, auto‑injectors and drug‑device combination products with innovative packaging materials. For these items, the packaging system does not merely store the drug; it actively participates in drug delivery. Evaluations must therefore cover packaging functionality, device performance and end‑use‑related risks. As a result, CCS assessments will need to be incorporated earlier in new‑product development workflows.

Actions for Manufacturers in Response to the New FDA CCS Draft Guidance

Although the two documents remain draft versions, the future regulatory direction is clearly defined. Manufacturers shall focus on holistic container closure system assessment rather than evaluation of isolated packaging components.

First, companies shall review their existing CCS risk‑assessment frameworks and establish scientifically robust evaluation strategies based on product characteristics, administration routes and packaging configurations. Second, manufacturers of sterile and high‑risk products shall refine their CCI validation protocols, ensuring test methods accurately reflect packaging integrity and satisfy lifecycle management requirements. Furthermore, enhanced risk management for packaging materials is required, including compatibility studies, E&L evaluations and supplier data governance. Organisations developing complex packaging or combination products shall proactively assess the interface between packaging systems and device functionality to mitigate quality risks emerging at later development stages.

Enterprises That Should Prioritise Review of the Draft Guidance

While the FDA’s CCS draft guidance applies broadly to human pharmaceuticals and biologicals, the following categories of manufacturers face the most direct impacts:

1. Sterile dosage‑form manufacturers: For injectables, ophthalmic products and other sterile medicines, the container closure system underpins sterility assurance. Businesses shall pay close attention to CCIT requirements, packaging lifecycle validation and integrity evaluation within stability studies.
2. Biological product and biosimilar developers: Biological molecules are particularly susceptible to interactions with packaging materials. Enhanced assessment of packaging compatibility and E&L risks is necessary.
3. Manufacturers utilising complex packaging or drug‑device combination products: This portfolio covers pre‑filled syringes, auto‑injectors and inhalation products. Their packaging systems deliver both protective functions and drug‑delivery capabilities, requiring more comprehensive evaluation.
4. Companies adopting innovative packaging materials or preparing FDA submissions: These organisations may adopt the risk‑evaluation principles outlined in the drafts in advance to optimise packaging design, validation strategies and technical documentation.

In summary, the two new FDA draft guidance documents on container closure systems do not simply raise individual testing thresholds. They refine the overall quality‑evaluation framework for pharmaceutical packaging. The core changes can be summarised as a shift from component‑centric assessment to full‑system evaluation; from uniform prescriptive requirements to risk‑based assessment; and from isolated test results to end‑to‑end quality‑lifecycle management.

Going forward, the evaluation of pharmaceutical container closure systems will rely increasingly on scientific validation, risk analysis and lifecycle‑based quality management. By proactively understanding and adapting to this regulatory shift, pharmaceutical manufacturers can strengthen product quality control and better align with global regulatory expectations.